STOCK TITAN

Selecta Biosciences Inc - SELB STOCK NEWS

Welcome to our dedicated news page for Selecta Biosciences (Ticker: SELB), a resource for investors and traders seeking the latest updates and insights on Selecta Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Selecta Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Selecta Biosciences's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.58%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
clinical trial
Selecta Biosciences Inc

Nasdaq:SELB

SELB Rankings

SELB Stock Data

135.20M
94.00M
25.06%
47.78%
5.2%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Watertown

About SELB

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat